Search results
Showing 7351 to 7365 of 7708 results
June 2023: We are aware that the International Journal of Gynecology and Obstetrics has retracted a 2016 paper, which was used in committee decision making for this topic (IPG744). As the evidence base has now changed, it is returning to committee for re-discussion, see NICE's in-development webpage on balloon disimpaction of the baby’s head at emergency caesarean during the second stage of labour. Once the schedule for this has been confirmed, it will be communicated to stakeholders and published on the NICE website. In the meantime, please read the NIHR updated process to oversee the safe introduction of new procedures (PDF only).
September 2024: We have withdrawn this guidance. This is because the main evidence that the guidance was based on has been retracted by the journal. New NICE interventional procedures guidance is in development and the expected publication date is April 2025. Please see NICE's in-development webpage on balloon disimpaction of the baby’s head at emergency caesarean during the second stage of labour. In the meantime, please read the NIHR updated process to oversee the safe introduction of new procedures (PDF only).
Cemiplimab for treating metastatic or locally advanced cutaneous squamous cell carcinoma (TA592)
This guidance has been updated and replaced by NICE technology appraisal guidance TA802.
This guidance has been updated and replaced by NICE technology appraisal guidance TA1007.
Venglustat for treating gangliosidoses in people 2 years and over ID 6358
In development [GID-TA11601] Expected publication date: TBC
In development [GID-TA11074] Expected publication date: TBC
Nivolumab with ipilimumab for untreated advanced renal cell carcinoma (TA581)
This guidance has been updated and replaced by NICE technology appraisal guidance 780.
In development [GID-TA11146] Expected publication date: TBC
This medtech innovation briefing (MIB) has been replaced by NICE medical technologies guidance on GaitSmart rehabilitation exercise programme for gait and mobility issues.
This medtech innovation briefing has been updated and replaced by NICE medical technologies guidance 76.
In development [GID-TA11631] Expected publication date: TBC
Voxelotor for treating haemolytic anaemia caused by sickle cell disease (TA981)
NICE has withdrawn this guidance. Pfizer has informed the Medicines and Healthcare products Regulatory Agency (MHRA) that the product is being withdrawn. The recall notification is being shared with all healthcare professionals. No new people will start taking voxelotor in the UK. Healthcare professionals should discuss alternative treatment options with people currently having voxelotor.
Ventripoint Medical System Plus for measuring heart volume and function (MIB310)
February 2023: The medtech innovation briefing on Ventripoint Medical System Plus for measuring heart volume and function has been withdrawn as the company have withdrawn from the process.
This medtech innovation briefing has been replaced by NICE diagnostic guidance on heart failure algorithms for remote monitoring in people with cardiac implantable electronic devices.